Strata Critical Medical (SRTA) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Strata Critical Medical.

Research analysts covering Strata Critical Medical.

Recent press releases and 8-K filings for SRTA.

Strata Closes Revolving Credit Facility

SRTA

Debt Issuance

New Projects/Investments

M&A

Strata Critical Medical, Inc. (SRTA) has closed a secured, asset-based revolving credit facility with JPMorgan Chase Bank, N.A..
The facility provides up to $30.0 million, with an option to increase to $50.0 million under certain conditions, and will be undrawn at close.
This credit line is intended to support the company's acquisition strategy and improve capital efficiency.
Owned aircraft are excluded from the collateral package, maintaining their unencumbered status for potential future financing.

1 day ago

Strata Critical Medical Acquires Keystone Perfusion Services

SRTA

M&A

Guidance Update

New Projects/Investments

Strata Critical Medical, Inc. (SRTA) completed the acquisition of Keystone Perfusion Services LLC for $124 million in upfront consideration, paid approximately 88% in cash and 12% in stock. Keystone is projected to generate approximately $65 million of revenue and $13 million of Adjusted EBITDA in full-year 2025, with revenue expected to grow more than 50% in 2025 compared to 2024.
The acquisition establishes Strata as the only full-service organ transplant service provider and diversifies its operations into other medical services, with non-transplant services representing more than half of Keystone's revenue. Keystone management is eligible for up to $23 million in earn-outs based on achieving gross profit growth targets through 2028.
Strata updated its full-year 2025 financial guidance to reflect the acquisition, projecting revenue of $180 to $190 million and Adjusted EBITDA of $13 to $14 million.
If the Keystone acquisition had closed on January 1, 2025, Strata's pro forma full-year 2025 guidance would be revenue of $225 to $235 million and Adjusted EBITDA of $22 to $24 million.